Abstract Background. Previous studies have suggested that hyperhomocysteinemia may be a risk factor for venous thrombosis. Tb assess the risk of venous thrombosis associated with hyperhomocysteinemia, we studied plasma homocysteine levels in patients with a first episode of deep-vein thrombosis and in normal control subjects.
M
ILD hyperhomocysteinemia is an established risk factor (or atherosclcrosis and vascular disease. 1 ·-In ciassic homocystinuria, half the vascular complications are of venous origin, :i but until reccntly it has bcen unclear whether mild hyperhomocysteinemia is also a risk factor for venous thrombosis.
2 · 1 ' 5 In a casc-control stucly, Falcon et al. found that hyperhomocysteinemia was Ά risk faclor for thrombosis in people younger than 40 years of agc.
(> They rcportecl that the diffcrcncc in homocysteine levels between casc patients and control subjects was particularly evident after mcthionine loading (sincc mcthionine is a prccursor of homocysteine). Recently, wc found hyperhomocysteinemia to bc a risk factor for recurrcnt venous thrombosis in patients bctwecn 20 and 70 years of age, äs compared with controls from the gcncral population. 7 Although the results of thcse studies support the hypothesis that mild hyperhomocysteinemia is a risk factor for venous thrombosis, the studies werc not designed to cstimate the risk in the general population.
Wc measured homocysteine conccntrations in paticnls and matched control subjccls participating in the Leiden Thrombophilia Study. 8 "" This is a population-based casc-control study designed to measure the effect ofseveral acquired and genetic risk factors for thrombosis in the general population. Bccause of the data available on the study subjects, we were ablc to investigatc whether the effect of hyperhomocysteinemia was independent of other well-established risk factors for thrombosis, such äs a deficiency of protein G, protein S, or antithrombin; use of oral contraccptivcs; and pregnancy or recent childbirth. Recently, resistance lo activated prolein G caused by a single point mutation in the factor V gcnc (factor V Leiden) has been rcported to bc the most common hercditary cause of venous thrombosis. 12 Since hyperhomocysteinemia also appears to bc common, we cxamincd the risk of thrombosis in pcrsons with both abnormaliücs.
METHODS
The methods by which blood samples were obtained and intervic\\' data werc colleeted have been described elsewhcre.^" The stndy protocol was approved by the local elhics committce, and all participants gave thcir informed conscnt. Brietty, consccnlivc patients youngcr ihan 70 years of age wbo had a first episode of deep-vein thi ombosis, objcclivcly confirmcd (by impedancc plcthysmography, Dopplcr ultrasonography, compression ultrasonography, or conlrasl venography), between 1988 and 1993 and who had no known cancer were sclected from the tiles of three anticoagulation clinies in the Netherlands (in Leiden, Amsterdam, and Rotterdarn). These chnics monitor the anticoagulant trcatmcnt of virtually all patients in well-dcfincd geographic areas. Each patient was askcd to find bis or her own healthy control subject of the samc sex and age (within fwe years) by asking neighbors or friends. Wc restricted the prcscnl analysis to casc patients and controls who were seen at the Leiden Anticoagulation Clinic and whose blood samples werc processed and frozcn on site with minimal dclay. (Blood samples from participants in Amsterdam and Rotterdam were also processed in Leiden, which caused delays of several hours, and homocysteine measuremcnls were therefore less accuratc than those measured in samples from subjects in Leiden.
15 ) The total homocysteine conccntration was measured in citrated plasma by automatcd high-performancc liquid chromatography with reverse-phase Separation and fluoresccnt detection (witb a Gilson 232-401 sample processor, Spcctra-Physics 8800 solvent-delivery system, and Spcctra-Physics LC 304 fluorometer). Wc used the method described by Fiskcrstrand et al.
Li with somc modifications.'' If not otherwisc stated, hyperhomocysteinemia was defined äs a homocysteine levcl above the 95th percentile in the control group (18.5μιτκ>1 per liter).
Wc calculated matched odds ratios äs estimates of the relative risk of thrombosis for homocysteine values above a given point, with the matching factor takcn into account. The univariate matched odds ratio is the ratio of the number of pairs of case patients and controls in which the homocysteine valne for the casc patient was above the specificd level and the value for the control was below that level to the number of pairs in which the homocysteine value for the conlrol was above the spccified level and the value for the case patient was bclow that level. THE NEW ENGLAND JOURNAL OF MEDICINE March 21, 1996 a conditional logislic-regression algorithm by thc maximum-likclihood method, with Egret Software. We also invcstigated a possiblc dosc-rcsponse rclation by calculating odds ratios for several ranges of homocyslcinc concentrations in a conditional logistic model. In aclclition, we calculated odds ratios for men and women separately and for several age groups in order to study possiblc diffcrenccs in risk among thcsc subgroups. Wc further explored the differences in risk between men and womcn by taking risk factors specific to women into account -specifically, the use of oral contraccptivcs, prcgnancy, and rccent childbirth. We analyzed the risk of thrombosis among womcn less lhan 50 ycars old, both with and without thc inclusion of womcn with thesc risk factors, by calculating unmatchcd odds ratios. The use of unmalchccl odds ratios was necessary because in thc restricted groups many matchcd pairs would not havc been complete. Sincc the matchcd and unmatched odds ratios diel not diffcr substantially in any oi our analyscs, we considered this approach justiiicd.
Wc also assessed whcthcr thc increased risk associatcd with hyperhomocysteinenna in both sexes was confoundcd by othcr risk factors, such äs a dcficicncy of protein C, protein S, or antithrombin. Wc rcpeatcd the analysis alter cxcluding subjccls with abnormally low levels of thesc protcins (mcasurcd, äs prcviously reported, with a single lest") and estimatcd thc risk associalcd will) hypcrhomocystcincmia in pcrsons with normal protein C, protein S, and antilhrombin Icvcls.
Finally, wc looked at the possibility of an intcraction bctwccn hypcrhomocysteincmia and hetcrozygosity (carrier Status) for factor V Leiden, a rathcr common dcfcct that causcs resistance to activated protein C. We analyzed this intcraction by calculating univariatc odds ratios for thrombosis m persons with both or cithcr öl thrsc risk factors, äs compared with persons with neithcr risk faclor.
RESULTS
Thc ralio of male lo fcmale subjects among both thc casc paticnts and the controls was 1:1.3, and the mcan age was 44 years (ränge, 16 to 70 for the case patients and 16 to 71 for thc controls); both thcse variables were uscd in matching thc case patients and the controls.
Thc median plasma homocystcinc Icvcl in thc patients was 12.9 μηιοί per litcr (ränge, 4.8 to 60.2), and that in the controls was 12. Thc 95th perccntilc of thc homocystcinc Icvcls in the control group was 18.5 μιτιοί per litcr. Of thc 269 patients, 28 (10 pcrcent) exceeded this cutoff, äs compared with 13 (5 percent, by definition) in the control group. The matched odds ratio for decp-vcin thrombosis in subjects with a homocysteinc concentration abovc the 95th perccntilc, äs compared with those whose homocysteinc Icvcls were at or below that value, was 2.5 (95 percent confidcnce intcrval, 1.2 to 5.2). Whcn thc cutoff was set at thc 90th pcrcentilc, thc matchcd odds ratio was 1.9 (95 percent confidence interval, 1.1 to 3.3); it was 4.0 (95 percent confidence interval, 1.4 to 12.0) whcn the cutoff was the 97.5th pcrccntile (Tablc 1).
In order to evaluate the possibility of a dose-rcsponsc relation, we stratificd thc paticnts and controls according to their homocysteine concentrations and calculated odds ratios for thrombosis in thc paticnts at thc higher levels äs compared with thosc at the lowest level. As  Figurc 2 shows, the risk of thrombosis did not increase among subjects with homoeysteinc levels up to 18 μιτιοί per liter; the risk was greatly increased abovc 22 μηιοί per liter, howevcr, inclicating a thrcshold effcct rathcr than a continuous dose-rcsponsc rclation.
Odds ratios for several age groups and for men and women separately arc shown in Table 2 . For both scxcs, there was a sharp increase in thc risk of thrombosis associatcd with hypcrhomocysteincmia at inereasing ages. The overall odds ratio for thrombosis associatcd with hyperhomocysteinemia in women was 7.0 (95 percent confidence intcrval, 1.6 to 30.8), and in men it was 1.4 (95 percent confidence intcrval, 0.6 to 3.4), with the cutoff sct at thc 95th perccntilc of the homocysteine levels in thc control group (P = 0.067 for thc comparison between the sexcs). Whcn wc calculated thc 95th pcrccntile of thc distribulion of homocystcinc levels for men and womcn separately, wc found a 95th percentilc of 17.1 μπιοί per liter among women and 20.0 μιτιοί per liter among men in thc control group. Using thcsc cutoffs for hypcrhomocystcincmia, we found an odds ratio for thrombosis of 3.8 (95 percent confidence intcrval, 1.4 to 10.2) for womcn and 1.8 (95 percent confidence intcrval, 0.6 to 5.4) for men.
Thc higher rate of hyperhomocysteinemia in women than in men was prcscnl al all agcs, making it unlikcly thal thc diffcrence was cluc to risk factors specific to women, such äs thc use of oral contraccptivcs, rccenf childbirth, or prcgnancy. Indecd, whcn we cxcluclcd womcn wilh thcse risk factors, the unmatchcd odds ratio for thrombosis that was associated wilh hypcrhomocystcincmia (with the 95th pcrccntile ihr hol h sexes -18.5 μηιοί per litcr -äs the cutoff for hyperhomocysleincmia) among women under thc age of 50 was 11.3 (95 perccnl confidence intcrval, 2.7 to 46.0), whcrcas it was 2.8 (95 percent confidenee interval, 0.9 to 8.7) for all women, both those wilh and l hose without thcsc risk factors, under llic age of 50.
Of thc 269 palienls, 15 hacl prolein C deficirney, 7 h ad protein S deiicienry, and 10 hacl antithrombin dcficicncy. In the control group, 1'our hat! prolcin C dcficicncy, Füi cach cutolf point, subjccts classihcd äs ha\mg hypcihomocystcmemia weie thosc with plasma homocyslcmc 3c\els above the culoll value, and subjects elassified äs not having hypcr homocystememia wcie thosc with levcls at 01 bclow thc cutoff valuc ('below culoll') Tbe pcieentiles used äs culofls were toi (he disttibution of bomocysteine valucs in the contiof gioup Odds ratlos wcrc calculated äs the nsk of thiombosis in the stibjects with hypethoinocystememia äs Lompaied with that m the subjects withotit hypci homocystcincnua CI dcnotcs conhdcncc intcnal cighl had protcin S dcficicncy, and cight had anlithrombin deficicncy. After cxcluding thesc subjccts, we found a matchcd odds ratio for decp-vein ihrombosis of 2.6 (95 percent confidcnce interval, 1.2 to 5.9), äs comparcd with 2.5 (95 pcrccnt confidcnce interval, 1.2 to 5.2) \vhcn thosc subjccts werc included; this result shows that the cffect of homocystcine is largely indepenclent of thesc deficicnries in clotting-factor Inhibitors.
With respect to thc combination of factor V Leiden and hypcrhomocyslcincmia, wc calculated odds ratios for thrombosis in subjccts with both risk factors or either onc in rclation to subjects with ncithcr. A total of 47 of the paticnts carricd the factor V Leiden rautalion, äs comparcd with 7 of thc controls. Thc small numbcr with both dcfccts madc thc results statistically unstable and somewhat sensitive to the cutoff chosen for clevalcd homocysteine levels. When thc 90th pcrccntilc was uscd äs thc cutolf, thc odcLs ralio for thrombosis associated with thc presence of bolh risk factors (factor V Leiden and hypcrhomoeysteinernia) was 3.5 (95 percent confidcnce intcival, 0.7 lo 16.9); the odds ratios foi thrombosis associated with factor V Leiden alone and hyperhomocjsleinemia alonc, talculated sepaialely, were 9.5 and 2.2, rcspcctively. With the c )5th peicentile used äs thc cutofi, the odds latio foi the combination of risk factois was 2.0 (95 peiccnt tonddence inlcual, 0.4 to 10.9), \\heieas the odds ratios for cach i isk factor separately remamed virtualh unchanged. The statistical uncertainty of results based on these data is reflected in the wide confidence intervals, which do not exclude a relative risk äs high äs 16.9.
DlSCUSSION
Our study shows that hyperhomocysteinemia is a risk factor for deep-vein ihrombosis in the gencral population. Moreovcr, our results suggest that thc association between mild hyperhomocysteinemia and venous thrombosis is similar in degree to that reported for hyperhomocysteinemia and arterial vascular discase.' 1 ' 16 An unexpected finding was the substantial increase in the risk of thrombosis at the highest plasma homocysteine levels. Our data suggest that there may be a thrcshold levcl above which homocysteine has a thrombogcnic cffect.
Falcon et al. reported that hyperhomocysteinemia was a risk factor for juvenile thrombosis. 6 Our data imply that hyperhomocysteinemia is a risk factor for thrombosis in adult subjects äs well, since we found an increasing odds ratio with increasing age.
When we analyzed men and women separately, we found a differcnce in the risk of thrombosis associated with hyperhomocysteinemia. Even when we used diffcrcnt cutoff points for hyperhomocysteinemia in men and women by calculating the 95th percentiles of their homocysteine distributions in the control group separately, wc found that thc odds ratio was roughly twice äs high for women äs for men. This suggests that women may be more susceptible to thc pathologic effects of elcvatccl homocysteine levels, cven though their homocysteine levels arc in gencral lowcr than those of men.
1 This cffect cannot bc explained by risk factors spccific to women (such äs pregnancy, rccent childbirth, and oralcontraccpüve usc); an cffect of thesc risk factors was unlikcly in any casc bccausc thc differcnce betwccn men and women who did not havc such risk factors was even more pronouneed.
Hyperhomocysteinemia remained a risk factor for ΛΊΐΙι the nsk in those withoul hypcihomocystememia Cl dcnotcs conh icnce interval l1 he odds ratio was 12 0 (95 pcrccnt confidcncc jnlcrval ! 6 to 92 3) λΊιεη Ihe cutoll used was thc 90th peicendlc in the contiol gioup dccp-vcin thrombosis aftcr wc excludcd subjects with other wcll-established risk factors; that is, the association with thrombosis was not cxplaincd by thc prcscncc of other hercditary risk factors for thrombosis, such äs a dcficicncy of protem G, protem S, or antithrombin. The same was truc of the most common hereclitary risk factor for deep vcnous thrombosis, resistancc to activalcd protcin G, sincc hypcrhomocysteinemia also increased thc risk of thrombosis in those without this abnormality. We investigated a possiblc interaction between resistancc to activatcd protcin G (factor V Leiden) and hypcrhomocysteinemia. Although we found that the risk of thrombosis may be higher m carners of the mutation who havc hyperhomocysteinemia than in noncarriers with hyperhomocysteinemia, the combined effect in our subjects seemed smaller than for factor V Leiden alonc. Becausc of the small numbers mvolvcd, thc only rcasonablc conclusion is that thc two factors do not potentiatc each other.
Many hypotheses have been proposed to cxplain how hyperhomocysteinemia may lead to vcnous thrombosis and atheiosclerosis. One hypothesis is that homocysteine has a toxic effect on thc vascular cndothelium and on the clotting cascadc.
1 · 2 Scveral in vitro studies seem to support this view. 17 · 18 However, virtually all these studies used amounts of homocysteine that produced higher-than-physiologic concentrations. Alternatively, hyperhomocysteinemia may reflect abnormal methiomne metabolism that affects the methylation of DNA and cell membranes. 19 Elevated homocysteine levels may result from low levels of fohc acid, vitamm B 6 , or vitamm B u . Moreover, several genetic alterations in enzymes involved in homocysteine metabolism have been described. 20 22 It remains unclear whether hyperhomocysteinemia of different causes entails the same risk of thrombosis. Ncvertheless, it is well knowri that vitamin supplementation lowers homocysteine concentrations in almost all subjects with hyperhomocysteinemia, rcgardlcss of thc undcrlying causc.
We conclude that mild hyperhomocysteinemia is a risk factor for deep-vein thrombosis in the general population. The ncxt question to be answercd is whether homocystcine-lowering therapy -folic acid, Vitamin B 6 , or vitamin B currcnt vcnous thrombosis. 2 Wc arc tndcbtcd to Mi s T Vissci, Mi s A. \ an Bc< k, Mi s M T WB Ic Poik-l-Otholl, and Mis A de Giaal-Ikss lui ihon (\crllint assistanco
